MariMed (OTCMKTS:MRMD – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01), Zacks reports. MariMed had a negative net margin of 9.13% and a negative return on equity of 10.71%.
MariMed Stock Performance
Shares of MRMD stock traded up $0.00 on Wednesday, reaching $0.07. The stock had a trading volume of 1,419,244 shares, compared to its average volume of 582,543. The company has a quick ratio of 0.34, a current ratio of 0.92 and a debt-to-equity ratio of 1.78. The firm’s 50-day moving average is $0.07 and its two-hundred day moving average is $0.07. The firm has a market capitalization of $29.82 million, a price-to-earnings ratio of -1.85 and a beta of 1.54. MariMed has a 12 month low of $0.04 and a 12 month high of $0.16.
MariMed Company Profile
MariMed, Inc. is a U.S.-based cannabis company that develops, operates and manages licensed cannabis cultivation, processing and dispensary facilities. The company serves both medical and adult-use markets, where permitted by state law, and focuses on producing and distributing cannabis flower, concentrates, edibles, tinctures and other cannabis-infused products. MariMed markets products under brands that have included Betty’s Eddies, Nature’s Heritage, InHouse and Kalm Fusion. Its products are sold through the company’s retail operations and third-party dispensaries in its operating markets.
Read More
- Five stocks we like better than MariMed
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.
